Navigation Links
Genisphere Begins Collaborative and Sponsored Research Program with the University of Maryland
Date:4/26/2017

HATFIELD, Pa., April 26, 2017 /PRNewswire/ -- Genisphere LLC, provider of the 3DNA® drug delivery platform, has signed a collaborative and sponsored research agreement with the University of Maryland, through Dr. Silvia Muro. The overall goal of the partnership is to study the pharmacokinetics and pharmacodynamics of various 3DNA designs and formulations after in vivo administration. Additional aims involve targeting diseases of the vasculature as well as inflammatory responses, demonstrating various methods of endocytosis via appropriate targeting moieties, and studying the mode and mechanism of 3DNA crossing the blood-brain barrier. 

Dr. Muro is a recognized expert on cellular and subcellular interactions and transport, as well as in vivo targeting, pharmacokinetics, biodistribution, and effects of drugs and drug delivery vehicles. She has also developed proprietary technologies and methods in these fields. Dr. Muro was first to show Genisphere's DNA-based nanodevices could be modified to induce specific uptake mechanisms for intracellular delivery of diverse compounds. A follow-up publication in 2014 validated her prior demonstration of 3DNA as a drug delivery nanocarrier.

Dr. Muro explained, "We have previous evidence of active targeting of 3DNA after intravenous injection. The goal now is to expand our in vivo studies to additional animal models, evaluate different sized 3DNA molecules, study the impact of targeting, and compare routes of administration. We are looking forward to learning more about these nanoreagents and how they interact with cells as they deliver their cargo. Our early focus on pharmacokinetics and biodistribution will drive how the unique properties of this DNA nanoscaffold may be utilized to effectively reach diseased cells and cross the blood-brain barrier. My lab has developed several tools to study nanoparticles and their interaction with biological membranes and barriers."

Bob Getts, Genisphere's Chief Science Officer, said "This collaboration, a decade in the making, is key for Genisphere. We want to build on the foundation of knowledge we have accumulated over the last few years integrating Dr. Muro's experience with 3DNA nanocarriers as well as her broad expertise in the targeted delivery and nanotechnology fields. The publications we expect from this partnership will be fundamental, and will also provide specific guidance for future applications as we build our drug pipeline in cardiovascular disease, oncology and neurotherapeutics." 

About Genisphere
Genisphere LLC is the provider of the 3DNA® platform for targeted drug delivery. 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA® nanocarriers are engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic-acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead compounds based on 3DNA® nanotechnology. For more information, please visit http://genisphere.com

For more information contact:
Jessica Bowers
Marketing Communications, Genisphere
215-996-3027
156118@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genisphere-begins-collaborative-and-sponsored-research-program-with-the-university-of-maryland-300445881.html


'/>"/>
SOURCE Genisphere
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Genisphere Enters Collaborative Research Agreement with the University of Pennsylvania
2. MDNA Begins Global Roll-Out with Appointment of Distribution Partner in South Korea
3. Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK
4. First Center in Middle East With Elektas Versa HD Radiotherapy System Begins Treating Cancer Patients
5. Interpace Diagnostics Group Begins Trading on NASDAQ
6. Patient enrollment begins for PRESERVE, a large study of retrievable IVC filters
7. BNBuilders Begins Construction on the Illumina San Diego Facility Expansion
8. StemCutis Begins Phase I/II Clinical Trial in U.S. Using Allogeneic Mesenchymal Stem Cells (itMSCs) Intravenously Infused to Treat Cutaneous Photoaging
9. FedCentric Technologies, LLC Begins Collaboration With Frederick National Laboratory for Cancer Research
10. BioAmber Begins Commissioning of Sarnia Commercial Plant
11. DNA Spectrum Begins the Search For a New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... River Falls, Wisconsin (PRWEB) , ... July 25, 2017 , ... ... solutions for the food and beverage industry, offers Citri-Fi® 125. This natural citrus fiber ... used to thicken and extend real tomato in sauces, condiments and spreads. Today, more ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... and Canada who have proven their superior service quality as rated by hiring ... as an industry leader based on service quality ratings from their placed talent. ...
(Date:7/20/2017)... AUSTIN, TX (PRWEB) , ... July 20, 2017 ... ... platform focused on health-related quality of life, today announced its full advisory board. ... also announced the promotion of James Crooks, PhD, former VP of Engineering, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Crucial ... trial sites and study participants truly unified. TrialKit, a native mobile app, empowers ... Part 11) research studies entirely on mobile devices. With TrialKit, clinical researchers can ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):